Cyclacel Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
SCHEDULE: Bio Green Med CEO Boosts Stake to 20.58%
Datuk Dr. Doris Wong Sing Ee, CEO of Bio Green Med Solution, Inc., increased her beneficial ownership to 20.58% through a $6.3 million private purchase and an equity grant.
David E. Lazar has fully divested his beneficial ownership in Cyclacel Pharmaceuticals, Inc., reducing his stake to 0%.
Former Cyclacel Pharmaceuticals CEO David E. Lazar disclosed significant share sales and updated his beneficial ownership in an amended Schedule 13D filing.
SCHEDULE 13D: New CEO Acquires 70% Stake in Cyclacel Pharmaceuticals, Signifying Major Leadership Shift
Datuk Dr. Doris Wong Sing Ee has acquired a 70% beneficial ownership stake in Cyclacel Pharmaceuticals, Inc. for $6.3 million and has been appointed as the new Chief Executive Officer and Executive Director.
SCHEDULE 13D: Cyclacel Pharmaceuticals Undergoes Major Leadership and Ownership Shift with New Interim CEO's Strategic Share Sale
Cyclacel Pharmaceuticals, Inc. has announced significant changes in its leadership and ownership structure, including the appointment of a new Interim CEO who subsequently sold a substantial portion of his acquired shares.